Type 1 diabetes vaccine and preparation method thereof

Abstract

The invention relates to a type 1 diabetes vaccine and a preparation method thereof, and belongs to the technical field of biology. The preparation method comprises the following steps: inserting 190-320 site amino acid sequences of GAD65 and P277 peptides at 437-460 sites of HSP60 into the end 3' of a T7 bacteriophage DNA capsid protein 10B encoding gene through an auxiliary Th universal epitopeand a spacer subsequence so that a recombinant phage GAD65190-320+P277 / T7 is constructed by expressing amino acid sequences at the 190-320 sites of human GAD65, P277 peptides at the 437-460 sites of HSP60 and T7 10B into a fusion protein, and the recombinant phage GAD65190-320+P277 / T7 is further prepared into a vaccine. After the vaccine is used for immunizing an organism, the organism can be induced to generate specific antibodies aiming at GAD65 and 277, meanwhile, the organism is induced to generate immune tolerance, Treg cells are induced to generate, and blood sugar is reduced, so that the purpose of preventing and treating type 1 diabetes is achieved.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to a type 1 diabetes vaccine and a preparation method thereof. Background technique [0002] Type 1 diabetes (type 1diabetes mellitus, T1DM), also known as autoimmune diabetes, is a disease mediated by activated T lymphocytes caused by various reasons including viral infection, drug exposure, genetic factors and autoimmunity. Selective islet β-cell destruction and even functional failure caused by a series of autoimmune reactions lead to progressive aggravation of insulin deficiency in the body and chronic hyperglycemia, requiring lifelong insulin injections to control blood sugar. Since the discovery of insulin by Best and Banting in 1921, subcutaneous injection of insulin has been the most important means of treating T1DM. In recent years, with the widespread application of insulin slow-release pump technology and genetically engineered long-acting insulin, the blood suga...

AI Technical Summary

Problems solved by technology

[0005] However, most of the T1DM vaccines currently in clinical research are single-antigen vaccines, and the expression level of autoantibodies in T1DM will not remain unchanged, and will be affected by multiple factors such as the antigenic epitopes they recognize, the level of autoantigens, and the regulatory genes for antibody expression. change impact

Images